Skip to main content

A phase 1 study of intravenously administered TR-701 FA in subjects with advanced renal impairment

Introduction

The objective of the study was to characterize the safety of tedizolid phosphate (TR-701 FA) and the pharmacokinetics of tedizolid (TR-700), its microbiologically active moiety, in subjects with advanced renal impairment (eGFR <30 ml/minute/1.73 m2, not on dialysis) compared with matched subjects with normal renal function (eGFR ≥80.0 ml/minute/1.73 m2).

Methods

Eight subjects with advanced renal impairment and eight matched controls (by age, gender, and body mass index) received a single intravenous infusion of 200 mg TR-701 FA. Serial plasma PK samples were collected from pre-dose through 72 hours post-dose. Plasma samples were analyzed for TR-700 and the following pharmacokinetic parameters were calculated: Cmax, tmax, AUC0−∞, AUC0−t λz, CLsys, and plasma t 1 / 2 .

Results

Baseline eGFR ranged from 7 to 28 ml/minute/1.73 m2 (including three subjects with eGFR <15 ml/minute/1.73 m2). The pharmacokinetics of TR-700 was essentially unchanged in subjects with advanced renal impairment relative to a matched control group. Approximately 8% lower AUC and nearly identical Cmax values were observed in renal impaired subjects relative to matched controls, and other pharmacokinetic parameters were also similar between groups. See Table 1.

Table 1 Pharmacokinetic parameters of tedizolid in control and renal impaired subjects

Conclusion

The TR-700 plasma pharmacokinetic results from this study provide support that no dose adjustment is needed in subjects with advanced renal impairment.

Acknowledgements

Trial registration: NCT01452828.

Author information

Affiliations

Authors

Corresponding author

Correspondence to S Flanagan.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Flanagan, S., Morris, D., Boyea, T. et al. A phase 1 study of intravenously administered TR-701 FA in subjects with advanced renal impairment. Crit Care 17, P25 (2013). https://doi.org/10.1186/cc12641

Download citation

Keywords

  • Pharmacokinetic Parameter
  • Dose Adjustment
  • Matched Control
  • Normal Renal Function
  • Matched Control Group